JP2011521618A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521618A5
JP2011521618A5 JP2010545281A JP2010545281A JP2011521618A5 JP 2011521618 A5 JP2011521618 A5 JP 2011521618A5 JP 2010545281 A JP2010545281 A JP 2010545281A JP 2010545281 A JP2010545281 A JP 2010545281A JP 2011521618 A5 JP2011521618 A5 JP 2011521618A5
Authority
JP
Japan
Prior art keywords
tissue
cancer
primary
ube2s
tyms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010545281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521618A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/033117 external-priority patent/WO2009100159A2/en
Publication of JP2011521618A publication Critical patent/JP2011521618A/ja
Publication of JP2011521618A5 publication Critical patent/JP2011521618A5/ja
Abandoned legal-status Critical Current

Links

JP2010545281A 2008-02-04 2009-02-04 Ｐａｒｐ仲介疾患を診断および治療する方法 Abandoned JP2011521618A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2607708P 2008-02-04 2008-02-04
US61/026,077 2008-02-04
PCT/US2009/033117 WO2009100159A2 (en) 2008-02-04 2009-02-04 Methods of diagnosing and treating parp-mediated diseases

Publications (2)

Publication Number Publication Date
JP2011521618A JP2011521618A (ja) 2011-07-28
JP2011521618A5 true JP2011521618A5 (enExample) 2012-03-22

Family

ID=40952673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545281A Abandoned JP2011521618A (ja) 2008-02-04 2009-02-04 Ｐａｒｐ仲介疾患を診断および治療する方法

Country Status (13)

Country Link
US (1) US20090275608A1 (enExample)
EP (1) EP2250282A4 (enExample)
JP (1) JP2011521618A (enExample)
KR (1) KR20100112192A (enExample)
CN (1) CN101999002A (enExample)
AU (1) AU2009212401A1 (enExample)
CA (1) CA2713156A1 (enExample)
CO (1) CO6331372A2 (enExample)
IL (1) IL207360A0 (enExample)
MA (1) MA32136B1 (enExample)
MX (1) MX2010008572A (enExample)
RU (1) RU2010136966A (enExample)
WO (1) WO2009100159A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565654A (en) 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US20120059228A1 (en) * 2009-03-16 2012-03-08 The Research Foundation Of State University Of New York Methods for detecting endometriosis
US9771618B2 (en) * 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
TWI449911B (zh) * 2010-01-29 2014-08-21 Nat Defense Medical Ct 免疫球蛋白ａ型腎小球腎炎之分子標記及其應用
WO2011133918A1 (en) * 2010-04-23 2011-10-27 Isis Pharmaceuticals, Inc. Modulation of gm3 synthase (gm3s) expression
US20120094859A1 (en) * 2010-10-19 2012-04-19 Eva Redei Methods for detection of depressive disorders
US20140162887A1 (en) * 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
RU2013153096A (ru) * 2011-04-29 2015-06-10 Орхус Университет Способ определения клинически значимой гипоксии при раке
KR101439856B1 (ko) * 2011-06-02 2014-09-17 한국생명공학연구원 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
CN104845992B (zh) * 2011-09-16 2018-09-14 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
GB201202319D0 (en) * 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2013134774A1 (en) * 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
WO2013152301A1 (en) * 2012-04-05 2013-10-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. O-glycan pathway ovarian cancer signature
JP6263117B2 (ja) 2012-05-11 2018-01-17 公益財団法人微生物化学研究会 抗ｃｘａｄｒ抗体
WO2013183964A1 (ko) * 2012-06-07 2013-12-12 한양대학교 산학협력단 폐암 진단 및 치료를 위한 표적 단백질
US9903870B2 (en) 2012-10-04 2018-02-27 The Wistar Institute Of Anatomy And Biology Methods and compositions for the diagnosis of ovarian cancer
CN104704365B (zh) * 2012-10-15 2016-07-27 国立大学法人名古屋大学 精神分裂症标记物组及其利用
WO2014067038A1 (zh) * 2012-10-29 2014-05-08 广州百赫医疗信息科技有限公司 治疗人类adsl缺陷症的靶点、制剂及方法
US20140148357A1 (en) * 2012-11-29 2014-05-29 Vanderbilt University Characterizing Gastro-Intestinal Disease
CA2909091C (en) * 2013-04-09 2021-11-02 The Board Of Trustees Of The University Of Illinois Tumor-selective combination therapy
JP2016530545A (ja) * 2013-09-17 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 卵巣がんに関するバイオマーカー
KR101664291B1 (ko) * 2014-04-25 2016-10-13 대한민국 Ｈⅰｖ-1 ｔａｔ의 전사 활성을 조절하는 신규 공활성인자 nucks1
US20170283882A1 (en) * 2014-09-05 2017-10-05 Duke University Methods and therapeutics relating to mrna biomarkers for clinical prognosis of cancer
US10646185B2 (en) * 2015-01-15 2020-05-12 Koninklijke Philips N.V. iFR-CT
US11156599B2 (en) * 2015-03-19 2021-10-26 The Johns Hopkins University Assay for telomere length regulators
CN105067822B (zh) * 2015-08-12 2017-05-24 中山大学附属肿瘤医院 用于食管癌诊断的标志物
CN105200137B (zh) * 2015-09-28 2018-11-30 北京泱深生物信息技术有限公司 Cers2基因及其表达产物作为骨质疏松症的诊治靶标
CN105274225B (zh) * 2015-10-22 2019-01-18 山东省眼科研究所 一种用于检测斑块状角膜营养不良病的snp位点
CN105256029B (zh) * 2015-10-22 2018-07-24 山东省眼科研究所 Chst6基因在制备检测斑块状角膜营养不良制品中的应用
US20170220750A1 (en) * 2016-02-01 2017-08-03 Dexcom, Inc. System and method for decision support using lifestyle factors
WO2017192397A1 (en) 2016-05-02 2017-11-09 Dexcom, Inc. System and method for providing alerts optimized for a user
AU2017318678A1 (en) * 2016-09-02 2019-03-21 The Johns Hopkins University MIF inhibitors and methods of use thereof
CN106492217B (zh) * 2016-10-31 2018-12-28 哈尔滨医科大学 Parp1抑制剂在制备逆转肿瘤细胞对氨甲蝶呤耐药性药物中的应用
CN106701920A (zh) * 2016-11-25 2017-05-24 苏州首度基因科技有限责任公司 一种预测结直肠癌肝转移的试剂盒和使用方法
CN106706925B (zh) * 2016-12-12 2018-08-10 北京大学人民医院 一种筛查或辅助诊断炎症性肠病的方法及适用于该方法的试剂盒
KR102014951B1 (ko) * 2017-01-06 2019-08-27 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
WO2018148598A1 (en) * 2017-02-10 2018-08-16 The Regents Of The University Of California Compositions for treating breast cancer
EP3593134A1 (en) * 2017-03-09 2020-01-15 Cleara Biotech B.V. Biomarkers for cellular senescence
CN107271670B (zh) * 2017-05-04 2019-10-11 厦门大学 Ppp1ca作为肝癌诊断和检测预后的标志物及其应用
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
US11739386B2 (en) 2017-07-21 2023-08-29 Genecentric Therapeutics, Inc. Methods for determining response to PARP inhibitors
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
WO2019077123A1 (en) * 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법
KR102043802B1 (ko) * 2017-12-01 2019-11-13 주식회사 유비프로틴 갑상선 여포암 특이적 단백질분해조절 효소 유전자를 포함하는 갑상선 여포암 바이오마커 및 이를 이용한 갑상선 여포암 진단정보제공방법
CN109897866A (zh) * 2017-12-11 2019-06-18 中国科学院大连化学物理研究所 一种逆转肝癌细胞sorafenib的耐药性的方法
KR102080161B1 (ko) * 2018-02-01 2020-02-21 사회복지법인 삼성생명공익재단 개인 맞춤형 의료를 위한 유전자 패널, 그를 구성하는 방법, 및 그를 이용한 개인 맞춤형 치료 방법
CN112292463A (zh) * 2018-05-15 2021-01-29 肿瘤学风险公司 用于预测癌症患者药物反应性的方法
CN110623960B (zh) * 2018-06-22 2022-08-19 成都山权江生物科技有限公司 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用
CN108784703B (zh) * 2018-07-05 2021-02-02 西南石油大学 一种中老年人可穿戴式呼吸监测方法
CN109234392A (zh) * 2018-09-28 2019-01-18 北京致成生物医学科技有限公司 标记物在制备乳腺癌检测、诊断或预后监测产品中的用途
KR20200048740A (ko) 2018-10-30 2020-05-08 (주)아모레퍼시픽 Dnaja1 발현 촉진 물질을 포함하는 피부 장벽기능 강화용 조성물 및 dnaja1 촉진 물질의 스크리닝 방법
SG11202108140SA (en) 2019-02-12 2021-08-30 Medpacto Inc Anti-bag2 antibody and methods of treating cancer
WO2020215057A1 (en) * 2019-04-18 2020-10-22 The Regents Of The University Of California Pharmacological mitigation of late-stage toxemia
KR102195895B1 (ko) * 2019-04-19 2020-12-28 한국생명공학연구원 STT(2-(5-Methyl-4-oxo-2-thioxo-1,3-thiazolidin-3-yl) ethanesulfonic acid))를 유효성분으로 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
KR102361734B1 (ko) * 2019-06-10 2022-02-14 연세대학교 산학협력단 뇌신경계 질환의 진단용 바이오마커
EP4003358B1 (en) 2019-07-26 2025-12-31 Health Research, Inc. TREATMENT OF P53 DEFICIENCY CANCERS
KR102055872B1 (ko) * 2019-08-20 2019-12-13 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN110592214B (zh) * 2019-09-06 2022-11-18 上海市东方医院（同济大学附属东方医院） Pgm2l1基因在制备用于诊断卵巢癌的标记物中的用途及诊断试剂和治疗药物
CN112546228A (zh) * 2019-09-10 2021-03-26 中国科学院上海营养与健康研究所 非igf1r结合型的物质在预防和/或治疗炎症性疾病中的应用
CN110747276B (zh) * 2019-11-22 2020-06-30 山东大学齐鲁医院 Bace2作为胶质瘤预后/诊断/治疗标志物的应用
KR102168498B1 (ko) * 2019-12-09 2020-10-21 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
WO2021145458A1 (ja) * 2020-01-16 2021-07-22 学校法人慶應義塾 胆汁酸を生成するための組成物
CN113252895A (zh) * 2020-02-10 2021-08-13 首都医科大学附属北京世纪坛医院 血清组织蛋白酶d在淋巴水肿疾病中的应用
US12578337B2 (en) * 2020-04-15 2026-03-17 Public University Corporation Nagoya City University Method for prognosis prediction of skin cancer and use thereof
CN111606969B (zh) * 2020-05-13 2023-02-03 四川大学 一种parp1蛋白降解剂及其在抗肿瘤中的应用
CN111518909B (zh) * 2020-05-19 2022-07-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Mettl2基因在制备检测结直肠癌氟尿嘧啶类药物治疗敏感性的试剂盒中的应用
JP2023530391A (ja) * 2020-05-19 2023-07-18 プロフェーズ ラボズ， インク． バレット食道の発症及び食道腺癌の進行を明らかにするマーカーについてのシステム及び方法
KR102185037B1 (ko) * 2020-10-14 2020-12-01 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN114480631B (zh) * 2020-10-28 2024-09-24 中山大学孙逸仙纪念医院 Inpp5f用于制备肝癌组织肿瘤预后、诊断或防治的药物的用途
KR102205224B1 (ko) * 2020-11-24 2021-01-20 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
KR102221671B1 (ko) * 2021-01-13 2021-03-02 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN114814218A (zh) * 2021-01-19 2022-07-29 首都医科大学附属北京世纪坛医院 α烯醇化酶及其多肽片段在淋巴水肿中的应用
CN112730850B (zh) * 2021-01-22 2022-11-01 广州医科大学附属肿瘤医院 一种肾纤维化生物标志物及其应用
KR102260250B1 (ko) * 2021-02-22 2021-06-03 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
KR102243705B1 (ko) * 2021-02-22 2021-04-23 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
WO2022182661A1 (en) * 2021-02-23 2022-09-01 Board Of Regents, The University Of Texas System Methods for prognosing, diagnosing, and treating colorectal cancer
CN113238060B (zh) * 2021-05-08 2022-10-11 迈克生物股份有限公司 用于预测或诊断心肌炎的试剂盒
CN113025707A (zh) * 2021-05-19 2021-06-25 北京中医药大学 生物标志物在制备诊断湿热困脾型2型糖尿病的产品中的应用、试剂盒
WO2022251658A1 (en) * 2021-05-28 2022-12-01 La Jolla Institute For Immunology T cell transcriptomic profiles in parkinsons disease, and methods and uses thereof
CN113476608A (zh) * 2021-07-27 2021-10-08 中国药科大学 一种用于治疗癌症的组合药物
CN113549702A (zh) * 2021-09-14 2021-10-26 北京大学第三医院（北京大学第三临床医学院） 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒
CN113604573A (zh) * 2021-09-14 2021-11-05 北京大学第三医院（北京大学第三临床医学院） 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒
CN115290894B (zh) * 2022-01-19 2023-05-12 郑州大学第一附属医院 Inpp5f的检测试剂在制备口腔癌诊断产品和/或预后评估产品中的应用
EP4469086A4 (en) * 2022-01-25 2026-01-21 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
CN114854844B (zh) * 2022-05-05 2025-08-19 浙江大学 Rbbp7基因/蛋白作为药物靶点在制备诊断及治疗男性不育疾病产品中的应用
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN115433774A (zh) * 2022-08-18 2022-12-06 浙江丰能医药科技有限公司 一种用于原发免疫性血小板减少症检测的生物标志物及其试剂盒
CN116148471B (zh) * 2022-11-01 2024-05-07 中南大学 肺动脉高压的生物标志物及其应用
CN116726179B (zh) * 2023-07-11 2025-06-27 中国人民解放军陆军军医大学第一附属医院 Aldh18a1在制备抗尤文氏肉瘤的药物中的应用
CN117589989B (zh) * 2023-10-12 2025-03-04 华中科技大学同济医学院附属同济医院 子宫内膜癌保育治疗耐药标志物、产品及应用
CN117305458B (zh) * 2023-10-20 2024-06-21 四川省医学科学院·四川省人民医院 TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒
CN118480603B (zh) * 2024-01-24 2025-03-28 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一组鼻咽癌诊断标志物及其检测试剂
CN120519581B (zh) * 2025-05-23 2025-11-21 江西省人民医院 Inpp5f蛋白在制备乳腺癌诊断和/或预后产品中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041653A (en) * 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5719151A (en) * 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
KR100447539B1 (ko) * 1995-08-02 2004-11-10 뉴캐슬 유니버시티 벤처스 리미티드 벤조이미다졸화합물과이를포함하는제약학적조성물및이화합물을이용한치료방법
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
AU741382B2 (en) * 1997-03-26 2001-11-29 Large Scale Biology Corporation Di-aryl ethers and their derivatives as anti-cancer agents
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6235748B1 (en) * 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6426415B1 (en) * 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
AU9297998A (en) * 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
NZ511825A (en) * 1998-11-27 2003-08-29 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
US6201020B1 (en) * 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) * 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
EP1148053A4 (en) * 1999-01-26 2002-03-06 Ono Pharmaceutical Co 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6531464B1 (en) * 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
AU2001264595A1 (en) * 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20020142334A1 (en) * 2001-01-30 2002-10-03 Brown Janice A. Methods of detecting poly(ADP-ribose) polymerase enzymatic activity
CA2456985A1 (en) * 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
ATE454893T1 (de) * 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
AU2004270187A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
JP2008513436A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
DE102005023834A1 (de) * 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituierte[(Phenylethanoyl)amino]benzamide
EP1836320A2 (en) * 2005-01-07 2007-09-26 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
NZ565654A (en) * 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
JP5289060B2 (ja) * 2006-01-17 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐインヒビターとの組合せ療法
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
RU2481830C2 (ru) * 2007-01-16 2013-05-20 Бипар Сайенсиз, Инк. Лекарственные препараты для лечения рака
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療

Similar Documents

Publication Publication Date Title
JP2011521618A5 (enExample)
EA201500373A1 (ru) Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор
Ghasemi et al. Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells
Koustas et al. Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models
Martinez-Useros et al. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Huang et al. IFI6 downregulation reverses oxaliplatin resistance of colorectal cancer cells by activating the ROS-induced p38MAPK signaling pathway
Wang et al. Melittin treatment suppressed malignant NSCLC progression through enhancing CTSB-mediated hyperautophagy
Qin-Ying et al. LAMC2 acts as a novel therapeutic target of cetuximab in laryngeal cancer.
Bai et al. Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer
Pryor et al. The emerging era of personalized therapy in squamous cell carcinoma of the head and neck
Shi et al. κ-Opioid receptor activation suppresses triple-negative breast cancer progression by inducing urea cycle dysfunction and mitochondrial damage in vitro and in mice
Ge et al. Upregulation of KCNMA1 facilitates the reversal effect of verapamil on the chemoresistance to cisplatin of esophageal squamous cell carcinoma cells.
Choi Genetic variations affecting response of radiotherapy
Chen et al. Estrogen receptor 1 and Aurora kinase A as potential diagnostic biomarkers for cervical cancer.
Singh et al. Anti-breast cancer activity of folate-chitosan nanoparticles loaded with irinotecan
Zhang et al. Extracorporeal shock waves effectively suppressed the proliferation and growth of colorectal cancer
Chen et al. Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma
Cho et al. A rare case of primary thymic adenocarcinoma mimicking small cell lung cancer
Liao et al. 224P WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Kong et al. EP126/# 770 Early octreotide therapy and medium-chain triglyceride diet in endometrial cancer patients following high para-aortic lymphadenectomy
Cadona et al. Overview of locally advanced breast cancer: A huge challenge to science
Tsai et al. Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma
Isidoro Meeting abstracts of Colossal Facet Conference-2nd World Congress on Cancer 2018 “Oncology and Cancer therapeutics in the 21st century”
Kot et al. Differences in expression profiling and biomarkers between histological colorectal carcinoma [s] subsets from the serrated pathway
Zeng et al. Non-SMC Condensin I Complex Subunit G (NCAPG) in Relevant Carcinomas: Physiopathologic Role and Mechanisms in Tumorigenesis